Sign in
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
Journal article   Open access  Peer reviewed

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

Maria T Abreu and William J Sandborn
Gastroenterology (New York, N.Y. 1943), Vol.159(6), pp.2013-2018.e7
2020-12
PMID: 32961246

Abstract

Ileum - pathology Humans Colon - drug effects Colon - immunology Ileum - immunology Cecum - diagnostic imaging Colitis, Ulcerative - immunology Ileum - drug effects Colonoscopy Crohn Disease - diagnosis Anti-Inflammatory Agents - therapeutic use Ileum - diagnostic imaging Clinical Trials as Topic - standards Colitis, Ulcerative - drug therapy Severity of Illness Index Anti-Inflammatory Agents - pharmacology Colon - pathology Biomarkers - analysis Treatment Outcome Crohn Disease - immunology Drug Discovery Cecum - drug effects Cecum - pathology Colon - diagnostic imaging Colitis, Ulcerative - diagnosis Crohn Disease - drug therapy Research Design - standards Cecum - immunology
url
https://doi.org/10.1053/j.gastro.2020.07.064View
Published (Version of record) Open

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.120 Inflammatory Bowel Diseases & Infections
1.120.139 Ulcerative Colitis
Web Of Science research areas
Gastroenterology & Hepatology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details